Drugs / ALETHINE
ALETHINE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00041379 | Mar 2002 → ? | lymphoma | LifeTime Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT00007839 | Aug 2000 → ? | lymphoma | LifeTime Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT00006466 | Aug 2000 → ? | plasma cell myeloma, precancerous condition | LifeTime Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALETHINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1183627 ↗ |
| Known as | Alethine, beta- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1183627 ↗ |
| Known as | beta alethine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006466 ↗ |
| Known as | Betathine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1183627 ↗ |
| Modality | Small molecule | — CHEMBL1183627 ↗ |
| Route | Subcutaneous | “Patients receive beta alethine subcutaneously every 2 weeks for 6 doses.” NCT00006466 ↗ |